



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2014	2013	% Change			2014	2013	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER SEGMENT <sup>(2)</sup></b>										
<b>BABY CARE</b>										
US	\$ 96	105	-8.6%	-8.6%	-	\$ 407	413	-1.5%	-1.5%	-
Intl	428	480	-10.8%	-4.8%	-6.0%	1,832	1,882	-2.7%	1.8%	-4.5%
WW	524	585	-10.4%	-5.5%	-4.9%	2,239	2,295	-2.4%	1.3%	-3.7%
<b>ORAL CARE</b>										
US	150	153	-2.0%	-2.0%	-	600	602	-0.3%	-0.3%	-
Intl	264	265	-0.4%	6.1%	-6.5%	1,047	1,020	2.6%	5.9%	-3.3%
WW	414	418	-1.0%	3.1%	-4.1%	1,647	1,622	1.5%	3.6%	-2.1%
<b>OTC</b>										
US	362	332	9.0%	9.0%	-	1,357	1,286	5.5%	5.5%	-
Intl	711	747	-4.8%	3.6%	-8.4%	2,749	2,742	0.3%	3.7%	-3.4%
WW	1,073	1,079	-0.6%	5.2%	-5.8%	4,106	4,028	1.9%	4.2%	-2.3%
<b>SKIN CARE</b>										
US	471	432	9.0%	9.0%	-	1,834	1,752	4.7%	4.7%	-
Intl	485	538	-9.9%	-3.7%	-6.2%	1,924	1,952	-1.4%	1.2%	-2.6%
WW	956	970	-1.4%	2.0%	-3.4%	3,758	3,704	1.5%	2.9%	-1.4%
<b>WOMEN'S HEALTH</b>										
US	7	38	-81.6%	-81.6%	-	50	280	-82.1%	-82.1%	-
Intl	301	310	-2.9%	6.0%	-8.9%	1,252	1,288	-2.8%	2.6%	-5.4%
WW	308	348	-11.5%	-3.6%	-7.9%	1,302	1,568	-17.0%	-12.6%	-4.4%
<b>WOUND CARE/OTHER</b>										
US	208	203	2.5%	2.5%	-	848	829	2.3%	2.3%	-
Intl	123	150	-18.0%	-11.6%	-6.4%	596	651	-8.4%	-6.3%	-2.1%
WW	331	353	-6.2%	-3.5%	-2.7%	1,444	1,480	-2.4%	-1.5%	-0.9%
<b>TOTAL CONSUMER</b>										
US	1,294	1,263	2.5%	2.5%	-	5,096	5,162	-1.3%	-1.3%	-
Intl	2,312	2,490	-7.1%	0.1%	-7.2%	9,400	9,535	-1.4%	2.3%	-3.7%
WW	\$ 3,606	3,753	-3.9%	0.9%	-4.8%	\$ 14,496	14,697	-1.4%	1.0%	-2.4%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2014	2013	Reported	Operational <sup>(1)</sup>	Currency	2014	2013	Reported	Operational <sup>(1)</sup>	Currency
<b>PHARMACEUTICAL SEGMENT <sup>(2) (3)</sup></b>										
<b>IMMUNOLOGY</b>										
US	\$ 1,816	1,726	5.2%	5.2%	-	\$ 7,111	6,591	7.9%	7.9%	-
Intl	762	676	12.7%	22.2%	-9.5%	3,082	2,599	18.6%	23.3%	-4.7%
WW	2,578	2,402	7.3%	10.0%	-2.7%	10,193	9,190	10.9%	12.2%	-1.3%
<b>REMICADE</b>										
US	\$ 1,052	982	7.1%	7.1%	-	4,155	3,891	6.8%	6.8%	-
US Exports <sup>(4)</sup>	244	367	-33.5%	-33.5%	-	1,078	1,339	-19.5%	-19.5%	-
Intl	376	363	3.6%	12.6%	-9.0%	1,635	1,443	13.3%	19.0%	-5.7%
WW	1,672	1,712	-2.3%	-0.4%	-1.9%	6,868	6,673	2.9%	4.1%	-1.2%
<b>SIMPONI/SIMPONI ARIA</b>										
US	164	112	46.4%	46.4%	-	544	404	34.7%	34.7%	-
Intl	182	142	28.2%	39.0%	-10.8%	643	528	21.8%	26.4%	-4.6%
WW	346	254	36.2%	42.2%	-6.0%	1,187	932	27.4%	30.0%	-2.6%
<b>STELARA</b>										
US	356	265	34.3%	34.3%	-	1,334	957	39.4%	39.4%	-
Intl	189	152	24.3%	34.3%	-10.0%	738	547	34.9%	37.3%	-2.4%
WW	545	417	30.7%	34.4%	-3.7%	2,072	1,504	37.8%	38.7%	-0.9%
<b>OTHER IMMUNOLOGY</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	15	19	-21.1%	-15.9%	-5.2%	66	81	-18.5%	-14.3%	-4.2%
WW	15	19	-21.1%	-15.9%	-5.2%	66	81	-18.5%	-14.3%	-4.2%
<b>INFECTIOUS DISEASES</b>										
US	564	302	86.8%	86.8%	-	3,112	1,077	*	*	-
Intl	512	642	-20.2%	-12.1%	-8.1%	2,487	2,473	0.6%	2.5%	-1.9%
WW	1,076	944	14.0%	19.5%	-5.5%	5,599	3,550	57.7%	58.6%	-0.9%
<b>EDURANT</b>										
US	6	5	20.0%	20.0%	-	24	15	60.0%	60.0%	-
Intl	84	68	23.5%	33.8%	-10.3%	341	221	54.3%	54.3%	0.0%
WW	90	73	23.3%	32.9%	-9.6%	365	236	54.7%	54.7%	0.0%
<b>INCIVO</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	5	107	-95.3%	-90.7%	-4.6%	226	517	-56.3%	-55.0%	-1.3%
WW	5	107	-95.3%	-90.7%	-4.6%	226	517	-56.3%	-55.0%	-1.3%
<b>OLYSIO/SOVRAD</b>										
US	256	13	*	*	-	1,943	13	*	*	-
Intl	65	10	*	*	-12.5%	359	10	*	*	-2.3%
WW	321	23	*	*	-2.5%	2,302	23	*	*	-0.4%
<b>PREZISTA</b>										
US	243	229	6.1%	6.1%	-	930	807	15.2%	15.2%	-
Intl	205	232	-11.6%	-3.5%	-8.1%	901	866	4.0%	5.9%	-1.9%
WW	448	461	-2.8%	1.3%	-4.1%	1,831	1,673	9.4%	10.4%	-1.0%
<b>OTHER INFECTIOUS DISEASES</b>										
US	59	55	7.3%	7.3%	-	215	242	-11.2%	-11.2%	-
Intl	153	225	-32.0%	-26.1%	-5.9%	660	859	-23.2%	-21.2%	-2.0%
WW	212	280	-24.3%	-19.6%	-4.7%	875	1,101	-20.5%	-18.9%	-1.6%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FOURTH QUARTER					TWELVE MONTHS				
	2014	2013	% Change			2014	2013	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>NEUROSCIENCE</b>										
US	645	611	5.6%	5.6%	-	2,452	2,584	-5.1%	-5.1%	-
Intl	1,006	1,040	-3.3%	5.1%	-8.4%	4,035	4,083	-1.2%	2.2%	-3.4%
WW	1,651	1,651	0.0%	5.3%	-5.3%	6,487	6,667	-2.7%	-0.6%	-2.1%
<b>CONCERTA/METHYLPHENIDATE</b>										
US	55	46	19.6%	19.6%	-	152	308	-50.6%	-50.6%	-
Intl	114	123	-7.3%	0.5%	-7.8%	447	474	-5.7%	-1.6%	-4.1%
WW	169	169	0.0%	5.7%	-5.7%	599	782	-23.4%	-20.9%	-2.5%
<b>INVEGA</b>										
US	96	87	10.3%	10.3%	-	360	316	13.9%	13.9%	-
Intl	65	67	-3.0%	7.0%	-10.0%	280	267	4.9%	8.7%	-3.8%
WW	161	154	4.5%	8.9%	-4.4%	640	583	9.8%	11.5%	-1.7%
<b>INVEGA SUSTENNA/ XEPLION</b>										
US	226	188	20.2%	20.2%	-	825	690	19.6%	19.6%	-
Intl	192	162	18.5%	27.8%	-9.3%	763	558	36.7%	39.1%	-2.4%
WW	418	350	19.4%	23.7%	-4.3%	1,588	1,248	27.2%	28.3%	-1.1%
<b>RISPERDAL CONSTA</b>										
US	104	113	-8.0%	-8.0%	-	427	440	-3.0%	-3.0%	-
Intl	190	208	-8.7%	-0.5%	-8.2%	763	878	-13.1%	-10.9%	-2.2%
WW	294	321	-8.4%	-3.1%	-5.3%	1,190	1,318	-9.7%	-8.2%	-1.5%
<b>OTHER NEUROSCIENCE</b>										
US	164	177	-7.3%	-7.3%	-	688	830	-17.1%	-17.1%	-
Intl	445	480	-7.3%	0.8%	-8.1%	1,782	1,906	-6.5%	-2.4%	-4.1%
WW	609	657	-7.3%	-1.4%	-5.9%	2,470	2,736	-9.7%	-6.9%	-2.8%
<b>ONCOLOGY</b>										
US	334	216	54.6%	54.6%	-	1,157	848	36.4%	36.4%	-
Intl	878	897	-2.1%	6.7%	-8.8%	3,300	2,925	12.8%	16.0%	-3.2%
WW	1,212	1,113	8.9%	16.0%	-7.1%	4,457	3,773	18.1%	20.6%	-2.5%
<b>VELCADE</b>										
US	-	-	-	-	-	-	-	-	-	-
Intl	418	524	-20.2%	-12.1%	-8.1%	1,618	1,660	-2.5%	1.1%	-3.6%
WW	418	524	-20.2%	-12.1%	-8.1%	1,618	1,660	-2.5%	1.1%	-3.6%
<b>ZYTIGA</b>										
US	255	211	20.9%	20.9%	-	971	750	29.5%	29.5%	-
Intl	340	284	19.7%	29.9%	-10.2%	1,266	948	33.5%	36.1%	-2.6%
WW	595	495	20.2%	26.0%	-5.8%	2,237	1,698	31.7%	33.1%	-1.4%
<b>OTHER ONCOLOGY</b>										
US	79	5	*	*	-	186	98	89.8%	89.8%	-
Intl	120	89	34.8%	43.9%	-9.1%	416	317	31.2%	34.2%	-3.0%
WW	199	94	*	*	-8.6%	602	415	45.1%	47.4%	-2.3%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>FOURTH QUARTER</b>					<b>TWELVE MONTHS</b>				
	<b>2014</b>	<b>2013</b>	<b>% Change</b>			<b>2014</b>	<b>2013</b>	<b>% Change</b>		
			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>			<b>Reported</b>	<b>Operational <sup>(1)</sup></b>	<b>Currency</b>
<b>TOTAL OTHER</b>										
US	997	696	43.2%	43.2%	-	3,600	2,848	26.4%	26.4%	-
Intl	485	490	-1.0%	6.0%	-7.0%	1,977	2,097	-5.7%	-3.4%	-2.3%
WW	1,482	1,186	25.0%	27.9%	-2.9%	5,577	4,945	12.8%	13.8%	-1.0%
<b>PROCRIT/EPREX</b>										
US	177	168	5.4%	5.4%	-	715	795	-10.1%	-10.1%	-
Intl	125	139	-10.1%	-3.2%	-6.9%	523	569	-8.1%	-6.2%	-1.9%
WW	302	307	-1.6%	1.5%	-3.1%	1,238	1,364	-9.2%	-8.4%	-0.8%
<b>XARELTO</b>										
US	428	271	57.9%	57.9%	-	1,522	864	76.2%	76.2%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	428	271	57.9%	57.9%	-	1,522	864	76.2%	76.2%	-
<b>OTHER</b>										
US	392	257	52.5%	52.5%	-	1,363	1,189	14.6%	14.6%	-
Intl	360	351	2.6%	9.6%	-7.0%	1,454	1,528	-4.8%	-2.4%	-2.4%
WW	752	608	23.7%	27.7%	-4.0%	2,817	2,717	3.7%	5.0%	-1.3%
<b>TOTAL PHARMACEUTICAL</b>										
US	4,356	3,551	22.7%	22.7%	-	17,432	13,948	25.0%	25.0%	-
Intl	3,643	3,745	-2.7%	5.8%	-8.5%	14,881	14,177	5.0%	8.3%	-3.3%
WW	\$ 7,999	\$ 7,296	9.6%	13.9%	-4.3%	\$ 32,313	\$ 28,125	14.9%	16.5%	-1.6%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FOURTH QUARTER					TWELVE MONTHS				
	2014	2013	% Change			2014	2013	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>MEDICAL DEVICES <sup>(2) (3) (7)</sup></b>										
<b>CARDIOVASCULAR CARE</b>										
US	\$ 222	210	5.7%	5.7%	-	\$ 862	808	6.7%	6.7%	-
Intl	336	324	3.7%	12.4%	-8.7%	1,346	1,269	6.1%	9.4%	-3.3%
WW	558	534	4.5%	9.8%	-5.3%	2,208	2,077	6.3%	8.3%	-2.0%
<b>DIABETES CARE</b>										
US	206	219	-5.9%	-5.9%	-	864	998	-13.4%	-13.4%	-
Intl	308	344	-10.5%	-1.5%	-9.0%	1,278	1,311	-2.5%	0.8%	-3.3%
WW	514	563	-8.7%	-3.2%	-5.5%	2,142	2,309	-7.2%	-5.3%	-1.9%
<b>DIAGNOSTICS <sup>(5)</sup></b>										
US	-	215	**	**	-	456	926	-50.8%	-50.8%	-
Intl	14	251	-94.4%	-90.5%	-3.9%	506	959	-47.2%	-44.9%	-2.3%
WW	14	466	-97.0%	-94.9%	-2.1%	962	1,885	-49.0%	-47.8%	-1.2%
<b>ORTHOPAEDICS</b>										
US	1,339	1,307	2.4%	2.4%	-	5,197	5,074	2.4%	2.4%	-
Intl	1,102	1,149	-4.1%	3.3%	-7.4%	4,478	4,435	1.0%	3.5%	-2.5%
WW	2,441	2,456	-0.6%	2.8%	-3.4%	9,675	9,509	1.7%	2.9%	-1.2%
<b>SPECIALTY SURGERY/OTHER <sup>(6)</sup></b>										
US	425	422	0.7%	0.7%	-	1,679	1,664	0.9%	0.9%	-
Intl	479	507	-5.5%	2.1%	-7.6%	1,862	1,840	1.2%	4.9%	-3.7%
WW	904	929	-2.7%	1.5%	-4.2%	3,541	3,504	1.1%	3.0%	-1.9%
<b>SURGICAL CARE</b>										
US	567	599	-5.3%	-5.3%	-	2,221	2,294	-3.2%	-3.2%	-
Intl	1,005	1,040	-3.4%	4.0%	-7.4%	3,955	3,975	-0.5%	2.6%	-3.1%
WW	1,572	1,639	-4.1%	0.6%	-4.7%	6,176	6,269	-1.5%	0.5%	-2.0%
<b>VISION CARE</b>										
US	195	228	-14.5%	-14.5%	-	975	1,036	-5.9%	-5.9%	-
Intl	451	491	-8.1%	1.7%	-9.8%	1,843	1,901	-3.1%	1.7%	-4.8%
WW	646	719	-10.2%	-3.5%	-6.7%	2,818	2,937	-4.1%	-1.0%	-3.1%
<b>TOTAL MEDICAL DEVICES</b>										
US	2,954	3,200	-7.7%	-7.7%	-	12,254	12,800	-4.3%	-4.3%	-
Intl	3,695	4,106	-10.0%	-2.3%	-7.7%	15,268	15,690	-2.7%	0.5%	-3.2%
WW	\$ 6,649	7,306	-9.0%	-4.7%	-4.3%	\$ 27,522	28,490	-3.4%	-1.6%	-1.8%

\* Percentage greater than 100%

\*\* Not meaningful

(1) Operational growth excludes the effect of translational curren

(2) Unaudited

(3) Prior year amounts have been reclassified to conform to current year product disclosure

(4) Reported as U.S. sales

(5) Reflects Diagnostics divestiture June 30, 2014

(6) Infection Prevention now reflected in Specialty Surgery/Other, previously reported independently

(7) Previously referred to as Medical Devices and Diagnostics